Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. - Wikidata - wikimedia - TriplyDB

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

http://www.wikidata.org/entity/Q37103095

about

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer Metabolic complications of androgen deprivation therapy for prostate cancer Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysis Recent progress in pharmaceutical therapies for castration-resistant prostate cancer Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy Cardiovascular, diabetes, and cancer strips: evidences, mechanisms, and classifications.Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate Cancer Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Cardiac and cognitive effects of androgen deprivation therapy: are they real?Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review.Contemporary role of androgen deprivation therapy for prostate cancer CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review.A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database Cardiovascular risk during hormonal treatment in patients with prostate cancer.Metabolic effects of androgen deprivation therapy Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.Risk stratification in the hormonal treatment of patients with prostate cancer Androgen deprivation therapy and cardiovascular risk.Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer.Radiation treatment for patients with intermediate-risk prostate cancer.Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer.An update on androgen deprivation therapy for prostate cancer.Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy.Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.Androgen deprivation therapy toxicity and management for men receiving radiation therapy Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?The relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancer Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer.Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective Radiotherapy and Hormone Treatment in Prostate Cancer Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

P2860

Q24193722-A3531F47-C81C-479F-986B-E9E180F0708A Q24616159-EC502474-7F30-4435-9C11-C9ADBC2C5BF2 Q26738281-924B1D7C-55D1-4BC4-B9A0-0A744C63B219 Q26777150-C37C4034-4B05-4B3F-A408-82ACB3B26C14 Q26801000-AED69724-D4B3-444E-9175-41BF0A22B550 Q27022567-07942B61-BB6E-4DAC-A8BC-85CCC15B431E Q27308917-D237A3DA-E8EE-40A9-9E8D-FA3558854C73 Q30487342-6C13D6FA-EB4B-42B7-AE97-3F95A596A238 Q33736308-6CB11470-AF07-4EE0-8017-3E6FD60F8FBF Q33819775-F629B5ED-A8D2-4334-A670-A6B90DE9EFC8 Q33977523-70A10D06-6E04-4CC8-B4D6-292A857A6480 Q34111628-A0E6D4F2-DF6D-453F-AB3B-AA3D158F2C18 Q34171941-8BA8465F-FD20-45B7-8236-BA6509EDB5A1 Q34211155-1EEB46E8-A1DA-4548-A303-D54A77A45017 Q34387852-BC26C9A5-9DC2-4698-8F83-48F7F7880184 Q34505196-CB7F44B8-35F3-4D36-B49E-2E4F425C69D3 Q34627540-4C5BEB37-AB94-4C6C-9096-D7C87B35E6C1 Q34663266-0A152B51-DDEB-4072-9A87-B58078704557 Q34721165-87C16943-E56C-4D48-8A7E-EB60771BA1B3 Q34962416-F43109EA-4849-415A-8BCE-7181080C6A15 Q35022837-9ED9A849-EFC8-4EF8-B4E4-7A826C091DB9 Q35076189-CBD0D432-C53A-4431-BAC0-DC9B8BE572D5 Q35229730-9CEFE98E-5FB7-44C8-A450-A0778BF98675 Q35635497-AE992644-84B9-4DFA-BD33-7F6CD7837F04 Q35947920-068520DE-AB0F-4BD3-A30B-05C9D9AEFDD3 Q35992830-2E24EA19-E021-419C-8FA1-F74184DDE6D6 Q36006317-9389F993-8C20-408E-AA28-45C94C5753E2 Q36289952-28803345-A5B8-4D26-9D2B-C3DCEE5440FD Q36360358-8BD6B0D5-A052-4350-AE05-564A8EBE05BB Q36450795-0071C809-2963-4049-89AF-34405196D500 Q36530136-E02A42C0-4473-45B8-8F97-3DD209344C5E Q36557840-7DD262B5-B977-4363-8156-D650FE849C1C Q36665817-44495F5D-ED99-49C6-B5E9-EC8C9D8D5C3A Q36668905-A0F8B2DF-A013-4322-B389-9D6F07688B72 Q36866314-77422F1D-DF84-4F31-8DE1-8AA154AFA24F Q36898849-EF3C65D2-3999-44B5-A8AF-EC94814E3356 Q37044229-D57A6D99-B298-4ECD-A31F-4A97DC0D5A2E Q37176612-2BAB0A4A-0D21-434A-96D5-DC0548F8F01B Q37390104-B593F394-E2A2-4EF4-ACA1-F247AE0B2CA5 Q37431937-20AF84AF-CC2B-44F8-82A6-7206CBD68371

P2860

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

http://www.wikidata.org/entity/Q37103095

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cardiovascular mortality after ...... d prostate cancer: RTOG 85-31.

@en

Cardiovascular mortality after ...... d prostate cancer: RTOG 85-31.

@nl

type

label

Cardiovascular mortality after ...... d prostate cancer: RTOG 85-31.

@en

Cardiovascular mortality after ...... d prostate cancer: RTOG 85-31.

@nl

prefLabel

Cardiovascular mortality after ...... d prostate cancer: RTOG 85-31.

@en

Cardiovascular mortality after ...... d prostate cancer: RTOG 85-31.

@nl

P1433

Q37103095-0E63598F-AD67-441A-8106-8F1B77A7D3D1

P1476

Q37103095-0CF05D29-3B88-4FD7-8DFC-D79CDD6EC88F

P2093

Q37103095-1939F596-9DB1-4A09-95F2-EB351F295BE4

Q37103095-4FD700CA-4EB2-4E88-A9F6-E02DFEC598AD

Q37103095-71428618-6234-432C-BC77-498ED574105C

Q37103095-7AF24DFD-BC34-426B-BB78-E9B783D15FD9

Q37103095-9848D856-0A0D-4B48-91C9-5643686E348B

Q37103095-BEBD7540-09FB-4E30-A572-76B9B32C6BBA

Q37103095-F69C0968-55A5-4D40-9BBE-7F746D412ED8

P2860

Q37103095-05C72A99-890C-497F-8DEF-5BC4F036F493

Q37103095-0A01F308-8037-4C9C-AEB1-B1EFAB6E219D

Q37103095-1D7FA255-DDC1-4839-A21C-8C7D77F13B47

Q37103095-210FBB36-0D08-4E1F-92B0-6E29400CD6A6

Q37103095-2C172C8C-6DD7-4AC8-A348-6BD6D550559F

Q37103095-388FAC42-5B49-47A1-ACE6-556DE183C115

Q37103095-58E72124-C803-4274-8B84-9E2DC42CD472

Q37103095-59C5CD2E-3BDB-4ECF-B159-7A939C9F4C48

Q37103095-5BA5DA30-1488-407B-9C07-B5D39B1B5236

Q37103095-5E9A5F20-B8CD-4D6C-A2C1-B6096B43582F

P304

Q37103095-CB917D7E-1071-446C-ABB9-C8CB71E49240

P31

Q37103095-ADF9FD24-2A7C-4C6F-A3A2-0DE095F7650A

P356

Q37103095-1F9A57E7-8400-4525-AFBD-0ABDB55CC7BF

P407

Q37103095-35B7DA9D-0A9C-4E97-A45C-DCAFAB45FF59

P433

Q37103095-0C124968-576F-4968-AE38-7F34164F302E

P478

Q37103095-07A7211D-1E22-468F-99DD-7EE042A5803F

P577

Q37103095-5D48BB28-7B90-430C-8BFE-2DF1CA0F972B

P698

Q37103095-086ED491-DBF8-46FA-BFA5-A26260910DE8

P921

Q37103095-69183295-E304-4A8F-87A3-62DD6615E7EF

P932

Q37103095-594A6091-F7D8-40CA-B609-B11C4EA677EE

P356

JCO.2007.12.3752

P1433

Journal of Clinical Oncology

P1476

Cardiovascular mortality after ...... d prostate cancer: RTOG 85-31.

@en

P2093

Gerald E Hanks

http://www.w3.org/2001/XMLSchema#string

Howard M Sandler

http://www.w3.org/2001/XMLSchema#string

Jason A Efstathiou

http://www.w3.org/2001/XMLSchema#string

Kyounghwa Bae

http://www.w3.org/2001/XMLSchema#string

Matthew R Smith

http://www.w3.org/2001/XMLSchema#string

Miljenko V Pilepich

http://www.w3.org/2001/XMLSchema#string

William U Shipley

http://www.w3.org/2001/XMLSchema#string

P2860

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health

The structural basis of bone fragility in men.

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

Changes in body composition during hormonal therapy for prostate cancer.

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.

Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.

The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study.

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.

P304

92-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.12.3752

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19047297

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

2645096

http://www.w3.org/2001/XMLSchema#string